Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that its subsidiary, Changchun JinSai Pharmaceutical Co., Ltd. (“JinSai Pharmaceutical”), has received written notification from the U.S. Food and Drug Administration (“FDA”) that the clinical trial application for the injection GenSci143 has been accepted, targeting the indication of advanced solid tumors.